Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kun-Lin Yang currently manages a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The prosecution activity is highly concentrated, as evidenced by the 1 pending office action currently on record. This action represents the entirety of the active workload for the company at this stage, suggesting a very specific or streamlined filing strategy.
The prosecution is handled by 1 distinct examiner, MOEHLMAN, ANDREW TERRY. This examiner is also identified as the busiest examiner for the portfolio, with 1 pending office action assigned. Such a level of concentration means that the outcome of the company's current prosecution efforts depends entirely on the perspective and requirements of MOEHLMAN, ANDREW TERRY. Practitioners should focus on the specific examination history and preferences of this individual.
Furthermore, the portfolio's activity is limited to 1 distinct art unit. This indicates a specific technical focus within the Biotechnology & Pharmaceuticals sector. For a practitioner, this means that the prosecution strategy does not need to account for varying standards across different art units or multiple examiners. The focus remains on the interactions with the assigned examiner within that art unit, allowing for a consistent approach.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOEHLMAN, ANDREW TERRY | 1 | 67.0% | +59.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18187797 | Method for Forming Fungi Fermentation Product Containing N-Acetylglucosamine to Convert Cancer Cells into Normal Cells Through Mesenchymal Epithelial Transition Mechanism | MOEHLMAN, ANDREW TERRY | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18187797 | Method for Forming Fungi Fermentation Product Containing N-Acetylglucosamine to Convert Cancer Cells into Normal Cells Through Mesenchymal Epithelial Transition Mechanism | MOEHLMAN, ANDREW TERRY | 1600 | §103 | Final Rejection | — | Pending | Mar 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKun-Lin Yang has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Andrew Terry Moehlman has the most, with 1 of Kun-Lin Yang's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
